Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

  • Andrzej J. Jakubowiak, Ivan Houisse, István Májer, Ágnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi
  • Expert Review of Hematology, October 2017, Taylor & Francis
  • DOI: 10.1080/17474086.2017.1391088

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/17474086.2017.1391088